Distinct effects of EGFR inhibitors on epithelial- and mesenchymal-like esophageal squamous cell carcinoma cells

Abstract

BackgroundEpidermal growth factor receptor (EGFR) plays a pivotal role in the pathophysiology of esophageal squamous cell carcinoma (ESCC). However, the clinical effects of EGFR inhibitors on ESCC are controversial. This study sought to identify the factors determining the therapeutic efficacy of EGFR inhibitors in ESCC cells.MethodsImmortalized-human esophageal epithelial cells (EPC2-hTERT), transformed-human esophageal epithelial cells (T-Epi and T-Mes), and ESCC cells (TE-1, TE-5, TE-8, TE-11, TE-11R, and HCE4) were treated with the EGFR inhibitors erlotinib or cetuximab. Inhibitory effects on cell growth were assessed by cell counting or cell-cycle analysis. The expression levels of genes and proteins such as involucrin and cytokeratin13 (a squamous differentiation marker), E-cadherin, and vimentin were evaluated by real-time polymerase chain reaction or western blotting. To examine whether mesenchymal phenotype influenced the effects of EGFR inhibitors, we treated T-Epi cells with TGF-β1 to establish a mesenchymal phenotype (mesenchymal T-Epi cells). We then compared the effects of EGFR inhibitors on parental T-Epi cells and mesenchymal T-Epi cells. TE-8 (mesenchymal-like ESCC cells)- or TE-11R (epithelial-like ESCC cells)-derived xenograft tumors in mice were treated with cetuximab, and the antitumor effects of EGFR inhibitors were evaluated.ResultsCells were classified as epithelial-like or mesenchymal-like phenotypes, determined by the expression levels of E-cadherin and vimentin. Both erlotinib and cetuximab reduced cell growth and the ratio of cells in cell-cycle S phase in epithelial-like but not mesenchymal-like cells. Additionally, EGFR inhibitors induced squamous cell differentiation (defined as increased expression of involucrin and cytokeratin13) in epithelial-like but not mesenchymal-like cells. We found that EGFR inhibitors did not suppress the phosphorylation of EGFR in mesenchymal-like cells, while EGFR dephosphorylation was observed after treatment with EGFR inhibitors in epithelial-like cells. Furthermore, mesenchymal T-Epi cells showed resistance to EGFR inhibitors by circumventing the dephosphorylation of EGFR signaling. Cetuximab consistently showed antitumor effects, and increased involucrin expression in TE-11R (epithelial-like)-derived xenograft tumors but not TE-8 (mesenchymal-like)-derived xenograft tumors.ConclusionsThe factor determining the therapeutic effects of EGFR inhibitors in ESCC cells is the phenotype representing the epithelial-like or mesenchymal-like cells. Mesenchymal-like ESCC cells are resistant to EGFR inhibitors because EGFR signaling is not blocked. EGFR inhibitors show antitumor effects on epithelial-like ESCC cells accompanied by promotion of squamous cell differentiation.Electronic supplementary materialThe online version of this article (doi:10.1186/s13046-017-0572-7) contains supplementary material, which is available to authorized users.

Functional graphene oxide as cancer-targeted drug delivery system to selectively induce oesophageal cancer cell apoptosis

“…EGFR overexpression could cause increased cancer cell proliferation, decreased cell apoptosis, enhanced cell motility and angiogenesis. EGFR has been widely reported to be overexpressed in oesophageal cancer [26,27]. In order to choose a targeting cell model, we investigated EGFR expression in different human oesophageal cancer cell lines KYSE-30, KYSE-150, EC9706, EC109 and human oesophageal epithelial HEEC cell.…”

Quercetin‐3‐methyl ether inhibits esophageal carcinogenesis by targeting the AKT/mTOR/p70S6K and MAPK pathways

“…Growth factors and growth factor receptor‐mediated signaling pathways play an important role in cancer . Among the pathways, consistent activation of the phosphoinositide 3‐kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is known to promote tumor growth and survival .…”

Purpurogallin is a novel mitogen‐activated protein kinase kinase 1/2 inhibitor that suppresses esophageal squamous cell carcinoma growth in vitro and in vivo

“…Despite remarkable advances in treatment of esophageal cancer in the fields of surgery, chemotherapy, and radiotherapy, the survival rate from 2007 to 2013 was <20% according to the SEER Cancer Statistics review (National Cancer Institute). Although several types of targeted therapies have been examined for ESCC, including epidermal growth factor receptor (EGFR) or fibroblast growth factor receptor (FGFR) inhibitors, these agents have shown disappointing responses for a number of reasons, including development of resistance through reactivation of the mitogen‐activated protein kinase (MAPK) pathway, mesenchymal phenotype, or expression of programmed death‐ligand 1 (PD‐L1) . Therefore, finding more effective and widely available ESCC cancer chemotherapeutic and chemopreventive agents is still highly challenging.…”

“…have shown disappointing responses for a number of reasons, including development of resistance through reactivation of the mitogenactivated protein kinase (MAPK) pathway, mesenchymal phenotype, or expression of programmed death-ligand 1 (PD-L1). [3][4][5] Therefore, finding more effective and widely available ESCC cancer chemotherapeutic and chemopreventive agents is still highly challenging. Recently, FGFR-mediated mitogen-activated protein kinase kinase (MEK)/extracellular signal-regulated kinase (ERK) signaling activation was shown to promote tumor growth in ESCC.…”